Prange was most recently executive vice president and CEO for the Global Animal Health, Medical and Dental Surgical Group at Henry Schein and a member of the Executive Committee. In this role, she led a business that generated over $6 billion of revenue across three different business units, growing the business to above-market levels in all business segments. Prior to her role at Henry Schein, she led the Urology and Pelvic Health business for Boston Scientific Corp. and served as general manager of the Micrus Endovascular and Codman Neurovascular business at Johnson & Johnson Company. In addition to general management roles, Prange has extensive experience in commercial and operational roles, including managing innovation pipelines and acquiring and integrating companies.
“I’m looking forward to joining the board of AtriCure and am in full support of their mission of reducing the global Afib epidemic and healing the lives of those affected,” said Prange. “I have met some terrific people and am excited about their strategy going forward.”
Florin is currently executive vice president at Zimmer Biomet Holdings. He was appointed to this position in July 2019 upon announcing his intention to retire from the company. Previously, he served as executive vice president and chief financial officer (CFO) of the company. In addition, he served as interim CEO of the company from July 2017 to December 2017. Prior to working at Zimmer Biomet Holdings, Florin was CFO for Biomet Inc. until the company merged with Zimmer Inc. and became Zimmer Biomet Holdings. Prior to working at Biomet, he held various roles at Boston Scientific Corp., CR Bard Inc., and Deloitte & Touche LLP.
“I am truly excited to join the AtriCure board,” said Florin. “As I dug into this opportunity it became clear to me that AtriCure is having a significant positive impact on patients with Afib by providing their doctors new and improved ways to treat this disease and related complications. AtriCure is well positioned to capitalize on this opportunity.”
“I am pleased that Karen and Dan have agreed to join the AtriCure Board of Directors,” said Michael Carrel, AtriCure president and CEO. “Their commercial and operating experience, along with their financial expertise will be incredibly beneficial to the management team as we continue our growth in the coming years. I am looking forward to working with and learning from both of them.”